Financial reports
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
ARS
2022 FY
Annual report to shareholders
4 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
15 Apr 24
8-K
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
15 Apr 24
8-K
Results of Operations and Financial Condition
15 Apr 24
8-K
Reviva Announces $30 Million Registered Direct Offering PricedĀ At-the-MarketĀ Under Nasdaq Rules
17 Nov 23
8-K/A
Changes in Registrant's Certifying Accountant
14 Nov 23
8-K
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
14 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
14 Nov 23
8-K
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
30 Oct 23
8-K
Changes in Registrant's Certifying Accountant
4 Oct 23
8-K
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
17 Aug 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
13 Feb 24
S-3
Shelf registration
2 Feb 24
424B5
Prospectus supplement for primary offering
17 Nov 23
424B3
Prospectus supplement
5 Apr 23
S-8
Registration of securities for employees
30 Mar 23
POS AM
Prospectus update (post-effective amendment)
30 Mar 23
424B4
Prospectus supplement with pricing info
18 Oct 22
S-1
IPO registration
6 Oct 22
D
Indefinite amount in equity / options / securities to be acquired, 3 investors
19 Sep 22
424B5
Prospectus supplement for primary offering
7 Sep 22
Proxies
DEF 14A
Definitive proxy
4 Oct 23
DEF 14A
Definitive proxy
11 Oct 22
DEF 14A
Definitive proxy
26 Oct 21
DEFA14A
Additional proxy soliciting materials
14 Sep 20
DEF 14A
Definitive proxy
9 Sep 20
PRE 14A
Preliminary proxy
25 Aug 20
DEF 14A
Definitive proxy
6 May 20
PRE 14A
Preliminary proxy
21 Apr 20
DEF 14A
Definitive proxy
6 Feb 20
PRE 14A
Preliminary proxy
16 Jan 20
Other
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
9 Feb 24
EFFECT
Notice of effectiveness
5 Apr 23
EFFECT
Notice of effectiveness
18 Oct 22
CORRESP
Correspondence with SEC
13 Oct 22
UPLOAD
Letter from SEC
12 Oct 22
EFFECT
Notice of effectiveness
23 Mar 22
EFFECT
Notice of effectiveness
23 Mar 22
EFFECT
Notice of effectiveness
3 Feb 22
Ownership
SC 13D/A
Bhat Laxminarayan
16 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D/A
VEDANTA PARTNERS, LLC
30 Nov 23
4
PARAG SAXENA
22 Nov 23
4
PARAG SAXENA
14 Nov 23
4
Purav Patel
14 Nov 23
4
Richard A Margolin
14 Nov 23
4
Leslie D. Funtleyder
14 Nov 23
SC 13D/A
Bhat Laxminarayan
5 May 23